FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044695093> ?p ?o ?g. }

• W2044695093 endingPage "2142" @default.
• W2044695093 startingPage "2131" @default.
• W2044695093 abstract "Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.BackgroundChronic renal disease is associated with oxidative stress and reduced nitric oxide availability which, in turn, promotes hypertension and further progression of renal damage. Most actions of nitric oxide are mediated by cyclic 3′,5′ guanosine monophosphate (cGMP) which is rapidly degraded by phosphodiesterases (PDE). Therefore, we investigated if inhibition of PDE-5 would retard the progression of chronic renal failure.MethodsWe studied rats with 5/6 nephrectomy treated with sildenafil (2.5 mg/kg-1/day-1) in two experimental protocols. In the first protocol, we started sildenafil therapy immediately after renal ablation and continued treatment for 8 weeks. Control groups consisted of rats with renal ablation treated with drug-free vehicle and sham-operated rats with and without sildenafil treatment.ResultsIn these studies, sildenafil treatment prevented hypertension and deterioration of renal function, reduced histologic damage, inflammation and apoptosis, delayed the onset of proteinuria, and preserved renal capillary integrity. In the second protocol we compared sildenafil with losartan (7.5 mg/kg-1/day-1) and the combination of both drugs in established renal disease, starting these drugs 4 weeks after 5/6 nephrectomy. Delayed sildenafil treatment failed to improve proteinuria and glomerulosclerosis but ameliorated hypertension and azotemia.ConclusionThese observations suggest that currently available PDE-5 inhibitors have potential clinical value in the treatment of chronic renal disease. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Chronic renal disease is associated with oxidative stress and reduced nitric oxide availability which, in turn, promotes hypertension and further progression of renal damage. Most actions of nitric oxide are mediated by cyclic 3′,5′ guanosine monophosphate (cGMP) which is rapidly degraded by phosphodiesterases (PDE). Therefore, we investigated if inhibition of PDE-5 would retard the progression of chronic renal failure. We studied rats with 5/6 nephrectomy treated with sildenafil (2.5 mg/kg-1/day-1) in two experimental protocols. In the first protocol, we started sildenafil therapy immediately after renal ablation and continued treatment for 8 weeks. Control groups consisted of rats with renal ablation treated with drug-free vehicle and sham-operated rats with and without sildenafil treatment. In these studies, sildenafil treatment prevented hypertension and deterioration of renal function, reduced histologic damage, inflammation and apoptosis, delayed the onset of proteinuria, and preserved renal capillary integrity. In the second protocol we compared sildenafil with losartan (7.5 mg/kg-1/day-1) and the combination of both drugs in established renal disease, starting these drugs 4 weeks after 5/6 nephrectomy. Delayed sildenafil treatment failed to improve proteinuria and glomerulosclerosis but ameliorated hypertension and azotemia. These observations suggest that currently available PDE-5 inhibitors have potential clinical value in the treatment of chronic renal disease." @default.
• W2044695093 created "2016-06-24" @default.
• W2044695093 creator A5030266408 @default.
• W2044695093 creator A5040139595 @default.
• W2044695093 creator A5042459437 @default.
• W2044695093 creator A5044648049 @default.
• W2044695093 creator A5045218389 @default.
• W2044695093 creator A5056238061 @default.
• W2044695093 creator A5087801865 @default.
• W2044695093 date "2005-11-01" @default.
• W2044695093 modified "2023-10-18" @default.
• W2044695093 title "Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage" @default.
• W2044695093 cites W1579851907 @default.
• W2044695093 cites W1841074395 @default.
• W2044695093 cites W1969782978 @default.
• W2044695093 cites W1975755598 @default.
• W2044695093 cites W1976693476 @default.
• W2044695093 cites W1979646999 @default.
• W2044695093 cites W1990800322 @default.
• W2044695093 cites W1996978408 @default.
• W2044695093 cites W2001454343 @default.
• W2044695093 cites W2002956145 @default.
• W2044695093 cites W2009851966 @default.
• W2044695093 cites W2010121133 @default.
• W2044695093 cites W2019469243 @default.
• W2044695093 cites W2025763306 @default.
• W2044695093 cites W2031733455 @default.
• W2044695093 cites W2040080433 @default.
• W2044695093 cites W2042063432 @default.
• W2044695093 cites W2045336146 @default.
• W2044695093 cites W2053097440 @default.
• W2044695093 cites W2057353595 @default.
• W2044695093 cites W2058385357 @default.
• W2044695093 cites W2066297692 @default.
• W2044695093 cites W2068751000 @default.
• W2044695093 cites W2074593226 @default.
• W2044695093 cites W2077202337 @default.
• W2044695093 cites W2078296550 @default.
• W2044695093 cites W2081765204 @default.
• W2044695093 cites W2090503365 @default.
• W2044695093 cites W2093323348 @default.
• W2044695093 cites W2123627837 @default.
• W2044695093 cites W2124216831 @default.
• W2044695093 cites W2127530565 @default.
• W2044695093 cites W2138268741 @default.
• W2044695093 cites W2139491374 @default.
• W2044695093 cites W2144555815 @default.
• W2044695093 cites W2147245252 @default.
• W2044695093 cites W2153625446 @default.
• W2044695093 cites W2156632978 @default.
• W2044695093 cites W2160246177 @default.
• W2044695093 cites W2163337513 @default.
• W2044695093 cites W2168234252 @default.
• W2044695093 cites W2169462493 @default.
• W2044695093 cites W2281542263 @default.
• W2044695093 doi "https://doi.org/10.1111/j.1523-1755.2005.00669.x" @default.
• W2044695093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16221212" @default.
• W2044695093 hasPublicationYear "2005" @default.
• W2044695093 type Work @default.
• W2044695093 sameAs 2044695093 @default.
• W2044695093 citedByCount "99" @default.
• W2044695093 countsByYear W20446950932012 @default.
• W2044695093 countsByYear W20446950932013 @default.
• W2044695093 countsByYear W20446950932014 @default.
• W2044695093 countsByYear W20446950932015 @default.
• W2044695093 countsByYear W20446950932016 @default.
• W2044695093 countsByYear W20446950932017 @default.
• W2044695093 countsByYear W20446950932018 @default.
• W2044695093 countsByYear W20446950932019 @default.
• W2044695093 countsByYear W20446950932020 @default.
• W2044695093 countsByYear W20446950932021 @default.
• W2044695093 countsByYear W20446950932022 @default.
• W2044695093 countsByYear W20446950932023 @default.
• W2044695093 crossrefType "journal-article" @default.
• W2044695093 hasAuthorship W2044695093A5030266408 @default.
• W2044695093 hasAuthorship W2044695093A5040139595 @default.
• W2044695093 hasAuthorship W2044695093A5042459437 @default.
• W2044695093 hasAuthorship W2044695093A5044648049 @default.
• W2044695093 hasAuthorship W2044695093A5045218389 @default.
• W2044695093 hasAuthorship W2044695093A5056238061 @default.
• W2044695093 hasAuthorship W2044695093A5087801865 @default.
• W2044695093 hasBestOaLocation W20446950931 @default.
• W2044695093 hasConcept C126322002 @default.
• W2044695093 hasConcept C126894567 @default.
• W2044695093 hasConcept C134018914 @default.
• W2044695093 hasConcept C159641895 @default.
• W2044695093 hasConcept C2776768464 @default.
• W2044695093 hasConcept C2777390665 @default.
• W2044695093 hasConcept C2778653478 @default.
• W2044695093 hasConcept C2779561371 @default.
• W2044695093 hasConcept C2780091579 @default.
• W2044695093 hasConcept C2780994212 @default.
• W2044695093 hasConcept C519581460 @default.
• W2044695093 hasConcept C71924100 @default.
• W2044695093 hasConcept C74534348 @default.
• W2044695093 hasConcept C98274493 @default.
• W2044695093 hasConceptScore W2044695093C126322002 @default.
• W2044695093 hasConceptScore W2044695093C126894567 @default.

• next